Palbociclib Induced Neutropenia; Risk Factors and Treatment Outcome in Metastatic Breast Cancer Patients - Trial NCT06076772
Access comprehensive clinical trial information for NCT06076772 through Pure Global AI's free database. This phase not specified trial is sponsored by Assiut University and is currently Not yet recruiting. The study focuses on Metastatic Breast Cancer. Target enrollment is 54 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Assiut University
Timeline & Enrollment
N/A
Nov 01, 2023
Dec 01, 2026
Primary Outcome
Investigator will evaluate the patients and treatment characters in counts and percentage of developing high-grade neutropenia induced by palbociclib.,assess treatment outcome as a progression free survival for palbociclib in patient with neutropenia,assess treatment outcome as overall survival for palbociclib in patient with neutropenia
Summary
Aim of the study to assess the neutropenia induced by Palbociclib in patient receiving
 Palbociclib in combination with hormonal treatment as first-line therapy in metastatic
 hormone receptor- positive HER2 negative breast cancer. To evaluate the risk factors for
 occurrence of neutropenia and treatment outcome as 2 years PFS and OS.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06076772
Non-Device Trial